【摘要】 目的:检测原发性肝癌患者血清中可溶性B7-H4(sB7-H4)的水平并探讨其临床意义。方法:应用ELISA夹心法检测38例原发性肝癌患者与51例正常人血清sB7-H4水平,探讨其临床意义。结果:原发性肝癌患患者血清sB7-H4水平为(52.90±23.26)μg/L,正常人血清sB7-H4水平(32.67±12.28)μg/L,两者比较差异有显著性意义(P<0.01),且原发性肝癌患者血清sB7-H4水平与AFP水平呈正相关;I/II期原发性肝癌患患者血清sB7-H4水平显著高于III/IV期患者;术后原发性肝癌患患者血清sB7-H4水平显著低于术前。结论:原发性肝癌患患者血清sB7-H4水平显著增高,且与临床分期、治疗情况呈正相关,提示sB7-H4可能与原发性肝癌的发病有关,检测sB7-H4对原发性肝癌的诊断及疗效评估有一定的意义。更多还原

【Abstract】 Objective:To detect soluble B7-H4(sB7-H4)in serum of primary hepatocarcinoma patients and discuss its clinical significances.Method: Sandwich ELISA was applied to test sB7-H4 in serum of 38 primary hepatocarcinoma patients and 51 healthy controls.Result:Serum sB7-H4 in patients is 52.90±23.26 μg/L whereas healthy controls’ is 32.67±12.28 μg/L.The difference between them showed significance(P<0.01).Serum sB7-H4 in patients positively correlated with AFP.And serum sB7-H4 in patients of phase I/II was significantly higher than that of phase III/IV.Serum sB7-H4 in postoperative patients was significantly lower than that of preoperative.Conclusion: Serum sB7-H4 of primary hepatocarcinoma patients increases significantly and positively correlates with clinical stages and therapeutic conditions,which implicates that sB7-H4 correlates with the occurrence of primary hepatocarcinoma.Detecting on sB7-H4 is helpful for primary hepatocarcinoma diagnosis and therapeutic effect evaluation.更多还原